- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07599696
Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
14. maj 2026 opdateret af: Thea Knowles, Michigan State University
Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease.
By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia.
The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Though intensive behavioral speech intervention is considered the "gold standard" for treating hypophonia in Parkinson's disease (PD), many individuals struggle to transfer or maintain these behavioral strategies into their daily communication.
This is because PD, affecting over six million people worldwide, is a progressive, neurodegenerative disorder that also impairs cognition, sensorimotor integration, and fatigue.
Speech amplification devices are a type of augmentative technology that have been shown to improve communication related outcomes in PD.
Amplification devices increase the volume of a person's natural speech and can be used on their own or to augment behavioral speech outcomes.
The specific acoustic mechanisms underlying these benefits are unknown, though previous evidence suggests that increased signal intensity alone is not responsible for improved auditory-perceptual outcomes.
The overall goal of this proposal is to identify the relationship between acoustic and perceptual consequences of amplification devices with and without the use of behavioral speech strategies.
Aim 1 of this proposal will quantify the acoustic and auditory-perceptual effects of speech amplification devices for talkers with PD.
In addition to using an amplification device, participants will speak with both their habitual speech style and a hyperarticulated, clear speech style.
Aim 2 will identify the contribution of resultant acoustic features as well as targeted acoustic enhancements that optimize intelligibility in amplified speech.
Acoustic modifications that impact the relative contributions of low to high frequency spectral energy will be made to a subset of the speech recordings from Aim 1.
These acoustic enhancements will serve to simulate potential technological improvements to amplification devices.
Naïve listeners will hear the speech recordings made in Aims 1 and 2 and will provide measures of listener accuracy and effort.
Improvements in speech intelligibility of amplified speech are hypothesized to be associated with acoustic measures that reflect relative greater high to low frequency components of the speech signal.
The most positive change is hypothesized to occur when talkers combine behavioral speech strategies with amplification compared to behavioral changes or amplified speech alone.
Furthermore, auditory-perceptual outcomes are hypothesized to improve following implementation signal enhancements that could be directly integrated into future amplification device development.
Collectively, this study will identify ways to maximize speech treatment outcomes of speech amplification devices through behavioral changes made by the talker or acoustic enhancements to the device output itself.
Results will guide behavioral treatment strategies and future device modifications that will improve the efficacy of speech amplifiers in this population.
This work is innovative for establishing ways to leverage behavioral speech strategies with advances in augmentative technology for PD.
It is theoretically significant for defining the role of spectral acoustics in auditory-perceptual outcomes in disordered speech.
It is clinically significant for advancing patient-centered augmentative speech treatment technology for PD.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
100
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Thea Knowles, PhD
- Telefonnummer: 517-353-6401
- E-mail: thea@msu.edu
Studiesteder
-
-
Michigan
-
East Lansing, Michigan, Forenede Stater, 48823
- Rekruttering
- Michigan State University
-
Kontakt:
- Thea Knowles, PhD
- Telefonnummer: 517-353-6401
- E-mail: thea@msu.edu
-
Ledende efterforsker:
- Thea Knowles, PhD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Dominant speakers of North American English
- Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
- Present with changes in their speech/voice
Exclusion Criteria:
- History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
- Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Speech Study
Single arm study: All speech conditions are administered.
|
Behavioral speech strategies + speech amplification
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Speech intensity
Tidsramme: Day 1
|
Decibel sound pressure level (dB SPL) measured from speech audio recordings
|
Day 1
|
|
Voice quality
Tidsramme: Day 1
|
Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings
|
Day 1
|
|
Articulation
Tidsramme: Day 1
|
Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.
|
Day 1
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Speech intelligibility
Tidsramme: From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
|
% words correctly understood by naive listeners (0% = no words correctly transcribed; 100% = all words correctly transcribed).
Listener participants transcribe speech recorded by speaker participants.
|
From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
|
|
Perceived Listener Effort
Tidsramme: From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.
|
% along a visual analogue scale (0 = "no effort required to understand the speech"; 100 = "maximal effort required to understand the speech").
Listener participants will rate speech recorded by speaker participants.
|
From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. marts 2024
Primær færdiggørelse (Anslået)
31. december 2027
Studieafslutning (Anslået)
31. maj 2028
Datoer for studieregistrering
Først indsendt
5. maj 2026
Først indsendt, der opfyldte QC-kriterier
14. maj 2026
Først opslået (Faktiske)
20. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
20. maj 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. maj 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Synukleinopatier
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Luftvejssygdomme
- Neuroadfærdsmæssige manifestationer
- Neurodegenerative sygdomme
- Otorhinolaryngologiske sygdomme
- Bevægelsesforstyrrelser
- Parkinsonlidelser
- Basal Ganglia Sygdomme
- Laryngeale sygdomme
- Kommunikationsforstyrrelser
- Sprogforstyrrelser
- Artikulationsforstyrrelser
- Patologiske tilstande, tegn og symptomer
- Opførsel
- Tegn og symptomer
- Meddelelse
- Verbal opførsel
- Parkinsons sygdom
- Taleforstyrrelser
- Stemmeforstyrrelser
- Dysartri
- Tale
Andre undersøgelses-id-numre
- 00008898
- R21DC021798 (U.S. NIH-bevilling/kontrakt)
- CurePSP CARES Grant - Knowles (Andet bevillings-/finansieringsnummer: CurePSP)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Parkinsons sygdom
-
University of LahoreAfsluttet
-
Abbott Medical DevicesBaylor College of Medicine; University of HoustonAfsluttet
-
Bial - Portela C S.A.Afsluttet
-
CND Life SciencesDigestive Disease Associates of CTRekrutteringParkinsons sygdom | Parkinson | PARKINSON SYGGE (lidelse) | Parkinsons sygdomForenede Stater
-
iRegene Therapeutics Co., Ltd.RekrutteringEn fase I/III klinisk undersøgelse til evaluering af NouvNeu001-injektion til multippel systematrofiMultipel systematrofi - Parkinson subtype (MSA-P)Kina
-
Danish Research Centre for Magnetic ResonanceUniversity Hospital Bispebjerg and FrederiksbergRekrutteringSund og rask | Parkinson | Administration af medicinDanmark
-
Mayo ClinicAfsluttet
-
Bezmialem Vakif UniversityRekrutteringParkinsons sygdom | Parkinson | Parkinsons sygdom (PD) | PARKINSON SYGGE (lidelse) | Parkinsons sygdomTyrkiet (Türkiye)
-
CND Life SciencesOregon Health and Science UniversityRekrutteringParkinsons sygdom | Parkinson | Parkinsons sygdom og Parkinsonisme | PARKINSON SYGGE (lidelse)Forenede Stater
-
AstraZenecaParexelRekrutteringAvancerede solide tumorerSpanien, Forenede Stater, Sydkorea, Det Forenede Kongerige
Kliniske forsøg med Behavioral speech strategies + speech amplification
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)AfsluttetSlag | Afasi | Afasi ikke flydendeForenede Stater
-
Pacific Northwest University of Health SciencesCadwell Industries, Inc.AfsluttetDøvhed | Lydopfattelse | LydkvalitetForenede Stater
-
M.D. Anderson Cancer CenterTrukket tilbage
-
Queen's University, BelfastWestern Health and Social Care TrustAfsluttetTrakeostomi | Meddelelse | Akut/kritisk sygdomDet Forenede Kongerige
-
Northwestern UniversityStanford UniversityAfsluttet
-
The University of Texas at DallasNational Institute on Deafness and Other Communication Disorders (NIDCD)Afsluttet
-
University of South FloridaNational Institute on Deafness and Other Communication Disorders (NIDCD)Rekruttering
-
Washington University School of MedicineCochlearAfsluttet
-
Arizona State UniversityUniversity of Washington; National Institute on Deafness and Other Communication...RekrutteringSunde emner | Stammen, udviklingsmæssigtForenede Stater
-
Hospices Civils de LyonAfsluttetPatienter med anterior åben bidfejl og som har haft gavn af en kæbekirurgisk operation | Spædbarnssvælgning og tungefejlstilling, der nødvendiggør tungegenoptræningFrankrig